OncoMatch

OncoMatch/Clinical Trials/NCT06034275

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Is NCT06034275 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including VIP943 (QW) and VIP943 (BIW) for acute myeloid leukemia.

Phase 1RecruitingVincerx Pharma, Inc.NCT06034275Data as of May 2026

Treatment: VIP943 (QW) · VIP943 (BIW) — Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Myelodysplastic Syndrome

Biomarker criteria

Required: IL3RA overexpression

Evidence of CD123 expression from a local laboratory.

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Lab requirements

Cardiac function

Clinically significant cardiac disease including congestive heart failure > NYHA Class II, evidence for coronary artery disease (eg, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months) or myocardial infarction within the past 6 months before first dose)

Clinically significant cardiac disease including congestive heart failure > New York Heart Association (NYHA) Class II), evidence for coronary artery disease (eg, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months or myocardial infarction within the past 6 months before first dose.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Alabama at Birmingham · Birmingham, Alabama
  • University of Cincinnati · Cincinnati, Ohio
  • TriStar Bone Marrow Transplant · Nashville, Tennessee
  • MD Anderson Cancer Center · Houston, Texas
  • Fred Hutchinson Cancer Center · Seattle, Washington

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify